Orange Book Patent Challenges at the PTAB

The Fish post-grant team stays current on all of the trends affecting post-grant practice at the USPTO so that we always have the most up-to-date information for our clients. As part of our recent Post-Grant for Practitioners webinar series, we outlined some statistical trends concerning challenges of Orange Book patents at the PTAB. Below is a summary of those statistics.

For more information about challenges of Orange Book patents at the PTAB, please see our webinar BioPharma Patents at the PTAB or contact Tasha Francis.

Hover over the graphs below for detail.

The opinions expressed are those of the authors on the date noted above and do not necessarily reflect the views of Fish & Richardson P.C., any other of its lawyers, its clients, or any of its or their respective affiliates. This post is for general information purposes only and is not intended to be and should not be taken as legal advice. No attorney-client relationship is formed.

Orange Book Patent Challenges at the PTAB

Legal Alert: USPTO Issues Proposed Rules on Discretionary Denial in PTAB Proceedings

Legal Alert: USPTO Issues Proposed Rules on Director Review

What’s New in Director Review? Lessons From the Delegated Rehearing Panel’s First Decisions.

Biologics and Biosimilars Landscape: IP, Policy, and Market Developments

When Does IPR Estoppel Apply to Product or System Art in District Court?

The Top Three Things Foreign Companies Should Keep in Mind When Considering IPR

Legal Alert: USPTO Proposes Rules Updating Motion to Amend Practice Before the PTAB

Strategic Use of Evidence at the Patent Trial and Appeal Board

Why the Effect of Vivint Has Been Minimal

USPTO Issues Proposed Rules on Pre-Issuance Internal Circulation and Review of PTAB Decisions